A Phase 2 interventional study of Acetaminophen (ACE) (1000 mg) and Commercial ACE (1000 mg) in Dental Pain, sponsored by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.. Completed at 1 site in United States. Open to participants aged 17 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-12-03.
Sponsored by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Toothache with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Toothache · United States.
Among the 54 studies in Toothache with a site in United States, this one is the 19th largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2014, is one of 20 in phase 2, and was the 34th registered.
142 studies on the registry are indexed under Toothache; 28 are open to participants now.
Browse Toothache studies →6 of the 54 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:
Cytogel Pharma, LLC · Sites in United States
Ages 18–45 · Healthy volunteers
University of Florida · Sites in United States
Ages 18+ · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 6–12 · Healthy volunteers
Cleveland Dental Institute · Sites in United States
Ages 20–60
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 17 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 11 · Phase 4 10
First in 2004; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 84 across 123 interventional studies indexed under Toothache.
Median enrollment 194 across the 50 interventional studies, 82 across the 4 observational. Of the 45 that completed or were terminated, 30 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Johnson & Johnson has 6 studies filed under Toothache — fewer than ten, so there is no comparison to draw.
4 of the studies in Toothache with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860141Loma Linda UniversityEfficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. | 2026-12 |
| NCT06330207University of FloridaAn Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC) | 2027-02-01 |
| NCT06691269University of Maryland, BaltimorePhotobiomodulation and Tooth Analgesia | 2027-06 |
| NCT07905105Cytogel Pharma, LLCA Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Toothache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a dental pain study evaluating the efficacy and safety of a single dose of test acetaminophen (ACE) (1000 mg) compared to commercial acetaminophen (1000 mg), ibuprofen (IBU) (400 mg), and placebo over a 6 hour period. Subjects will undergo dental extraction of three or four third molars.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Acetaminophen (ACE) (1000 mg) · Drug: Placebo
Drug: Commercial ACE (1000 mg) · Drug: Placebo
Drug: Commercial Ibuprofen (IBU) (400 mg) · Drug: Placebo
Drug: Placebo
2 Test ACE 500 mg tablets taken orally one time
2 ACE 500 mg caplets taken orally one time
2 IBU 200 mg soft-gels taken orally one time
2 placebo caplets for acetaminophen taken orally one time
2 placebo soft-gels for ibuprofen taken orally one time
2 placebo tablets for Test acetaminophen taken orally one time
Time weighted sum of pain intensity difference from 0-6 hours (SPID 0-6)
Time weighted sum of pain intensity difference scores from baseline over 6 hours. Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 6 Hours
Time weighted sum of pain intensity difference from 0-4 hours (SPID 0-4)
Time weighted sum of pain intensity difference scores from baseline over 4 hours. Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 4 Hours
Time to meaningful pain relief
Minutes until meaningful pain relief are achieved. Stopwatch is started after the subject takes the study medication. The subjects are instructed to stop the stopwatch when the relief from the starting pain is meaningful to them.
Time frame: Within 6 Hours
Time to first perceptible pain relief
Minutes until first perceptible pain relief is achieved. Stopwatch is started after the subject takes the study medication. The subject is instructed to stop the stopwatch when they first begin to feel any pain relief.
Time frame: Within 6 Hours
Time to confirmed first perceptible relief
Minutes until confirmed first perceptible pain relief are achieved. Stopwatch is started after the subject takes the study medication. The subject is instructed to stop the stopwatch when they first begin to feel any pain relief. The first perceptible pain relief is confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.
Time frame: Within 6 Hours
Time weighted sum of pain relief from 0-4 (TOTPAR 0-4)
Time weighted sum of pain relief scores over four hours. Pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 4 hours
Time weighted sum of pain relief from 0-6 (TOTPAR 0-6)
Time weighted sum of pain relief scores over six hours. Pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 6 hours
Duration of relief after dosing (time to rescue analgesic)
Minutes until rescue medication is given
Time frame: 6 Hours
Proportion of subjects taking a rescue analgesic by 6 hours
Percentage of subjects using rescue medication through six hours
Time frame: 6 Hours
Subject Global Evaluation assessed at hour 6 or at time of rescue
Patient assessment of the pain medication - number of subjects rating the medication they received as a pain reliever on a score of 0-4, where 0=poor, 1=fair, 2=good, 3=very good, 4=excellent
Time frame: 6 hours
Pain relief (PAR) scores at 0.25 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 0.25 Hours
Pain relief (PAR) scores at 0.5 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 0.5 Hours
Pain relief (PAR) scores at 0.75 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 0.75 Hours
Pain relief (PAR) scores at 1 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 1 Hours
Pain relief (PAR) scores at 1.25 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 1.25 Hours
Pain relief (PAR) scores at 1.5 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 1.5 Hours
Pain relief (PAR) scores at 2 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 2 hoursH
Pain relief (PAR) scores at 3 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 3 Hours
Pain relief (PAR) scores at 4 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 4 Hours
Pain relief (PAR) scores at 5 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 5 Hours
Pain relief (PAR) scores at 6 Hours
Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief
Time frame: 6 Hours
Pain intensity difference (PID) at 0.25 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 0.25 Hours
Pain intensity difference (PID) at 0.5 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 0.5 Hours
Pain intensity difference (PID) at 0.75 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 0.75 Hours
Pain intensity difference (PID) at 1 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 1 Hours
Pain intensity difference (PID) at 1.25 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 1.25 Hours
Pain intensity difference (PID) at 1.5 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 1.5 Hours
Pain intensity difference (PID) at 2 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 2 Hours
Pain intensity difference (PID) at 3 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 3 Hours
Pain intensity difference (PID) at 4 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 4 Hours
Pain intensity difference (PID) at 5 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 5 Hours
Pain intensity difference (PID) at 6 Hours
Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain
Time frame: 6 Hours
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Dec 2014 to primary completion in Apr 2015, 3 months.
Of 10 phase 2 interventional studies under Toothache, half reached primary completion within 3 months of starting (the median); a quarter within 3 and three quarters within 5. This study's 3 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. →